Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns respectively) of particulate air pollution have been produced.<\/p>
<\/p>
Public Health England (PHE) undertakes various air quality research projects, working with academic partners, to review the evidence of the health effects of air pollutants. In particular, regarding the health effects of PM0.1 and PM1, PHE has a research program that looks at various aspects of the health effects of PM0.1 (nanoparticles) through the inhalational route mainly focussed on manufactured materials. However, PHE has no plans to engage in work on the effects of PM1 particles on human health over the coming year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-19", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219269"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-19T17:29:50.437Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Air Pollution: Health Hazards"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213200 on Air Pollution and with reference to p165 of the World Health Organisation report, Review of evidence on health aspects of air pollution \u2013 REVIHAAP Project, if his Department will conduct research into PM1 and PM0.1.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/252", "label" : {"_value" : "Biography information for Dr David Drew"} } , "tablingMemberConstituency" : {"_value" : "Stroud"} , "tablingMemberPrinted" : [{"_value" : "Dr David Drew"} ], "uin" : "219268"} , {"_about" : "http://data.parliament.uk/resources/1058716", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058716/answer", "answerText" : {"_value" : "
Recent assessments have been undertaken of the health effects of long-term exposure to the air pollution mixture in the United Kingdom, but no separate assessments of the impact of PM1 and PM0.1 components (particulate matter with an aerodynamic diameter smaller than 1 or 0.1 microns respectively) of particulate air pollution have been produced.<\/p>
<\/p>
Public Health England (PHE) undertakes various air quality research projects, working with academic partners, to review the evidence of the health effects of air pollutants. In particular, regarding the health effects of PM0.1 and PM1, PHE has a research program that looks at various aspects of the health effects of PM0.1 (nanoparticles) through the inhalational route mainly focussed on manufactured materials. However, PHE has no plans to engage in work on the effects of PM1 particles on human health over the coming year.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-19", "_datatype" : "dateTime"} , "groupedQuestionUIN" : {"_value" : "219268"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-19T17:29:50.483Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Air Pollution: Health Hazards"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 5 February 2019 to Question 213200 and with reference to page six of the January 2013 report of the Health Effects Institute entitled Understanding the Health Effects of Ambient Ultrafine Particles, if he will implement the recommendations of that report on PM0.1 and PM1.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/252", "label" : {"_value" : "Biography information for Dr David Drew"} } , "tablingMemberConstituency" : {"_value" : "Stroud"} , "tablingMemberPrinted" : [{"_value" : "Dr David Drew"} ], "uin" : "219269"} , {"_about" : "http://data.parliament.uk/resources/1058750", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058750/answer", "answerText" : {"_value" : "
Over the last five years, implementation of the United Kingdom antimicrobial resistance (AMR) strategy has been overseen and driven by a cross-Government High Level Steering Group, chaired by the Chief Medical Officer for England.<\/p>
<\/p>
Professor Dame Sue Hill, Chief Scientific Officer for NHS England, leads work to deliver the Government\u2019s ambitions for diagnostics as part of the strategy. NHS England established the UK AMR Diagnostics Collaborative to support delivery of the United Kingdom\u2019s diagnostics ambitions for AMR. The Collaborative has played a valuable role in developing the diagnostics elements of the new UK five-year national action plan on AMR, published in January this year.<\/p>
<\/p>
The Department continues to work closely with the UK AMR Diagnostics Collaborative, which currently has no plans to publish a report.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:44:29.493Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "UK Antimicrobial Resistance Diagnostics Collaborative"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what (a) representations his Department has received on the work of the UK Antimicrobial Resistance (AMR) Diagnostics Collaborative and (b) discussions have taken place between his Department and members of that group; what the timetable is for the publication of the AMR Diagnostics Collaborative's report; and (c) if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1604", "label" : {"_value" : "Biography information for Mr Virendra Sharma"} } , "tablingMemberConstituency" : {"_value" : "Ealing, Southall"} , "tablingMemberPrinted" : [{"_value" : "Mr Virendra Sharma"} ], "uin" : "219373"} , {"_about" : "http://data.parliament.uk/resources/1058752", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058752/answer", "answerText" : {"_value" : "
No formal assessment has been made of the National AIDS Trust report however officials will consider its findings in the development of future drugs policy. The Government is concerned by the number of drug-related deaths and is supporting local areas to develop a more joined up approach to commissioning and delivering the range of services that are essential to supporting recovery and preventing drug-related deaths.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:45:27.307Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Drugs: Death"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the implications for his Department's policies of the findings of the National Aids Trust report, Drug-Related Deaths in England, published by the National Aids Trust, published on 5 February 2019; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3973", "label" : {"_value" : "Biography information for Grahame Morris"} } , "tablingMemberConstituency" : {"_value" : "Easington"} , "tablingMemberPrinted" : [{"_value" : "Grahame Morris"} ], "uin" : "219400"} , {"_about" : "http://data.parliament.uk/resources/1058753", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058753/answer", "answerText" : {"_value" : "
A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective.<\/p>
As the explanatory memorandum of the amending Statutory Instrument acknowledges, protocols for therapeutic or generic equivalents will not be suitable for all medicines and patients. For example, such protocols would not be suitable for medicines that need to be prescribed by brand for clinical reasons, such as biological medicines. In these cases, patients would always be referred to the prescriber for any decision about their treatment before any therapeutic or generic alternative is supplied.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:35:25.567Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the proposed amendments to the Human Medicines Regulation 2012, what treatment areas will be excluded from the serious shortage protocol for reasons of patient safety; and if he will publish a list of medicines and formulations that will be excluded as a result.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4127", "label" : {"_value" : "Biography information for Julie Elliott"} } , "tablingMemberConstituency" : {"_value" : "Sunderland Central"} , "tablingMemberPrinted" : [{"_value" : "Julie Elliott"} ], "uin" : "219427"} , {"_about" : "http://data.parliament.uk/resources/1058754", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058754/answer", "answerText" : {"_value" : "
A Serious Shortage Protocol is an additional tool to manage and mitigate medication shortages and may be used in the exceptional and rare situation when other measures have been exhausted or are likely to be ineffective. It can only be issued by Ministers and would only be introduced in the case of a serious shortage, if it would help manage the supply situation and if clinicians think it is appropriate, after discussion with the manufacturer and/or marketing authorisation holder.<\/p>
<\/p>
Any protocol would need to set out what alternative quantity, pharmaceutical form, strength, therapeutic equivalent or generic equivalent can be supplied. Supply in accordance with a protocol can only be made if the protocol is in date when a prescription is presented for dispensing, whether that prescription is an acute or a repeat prescription. If appropriate, the protocol could stipulate that it does not apply to a certain type of prescription.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2019-02-14", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-02-14T17:47:44.153Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-02-11", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Human Medicines (Amendment) Regulation 2019, what the system will be by which clinicians will be able to indicate whether or not an alternative (a) quantity, (b) strength, and (c) pharmaceutical form of medicine can be dispensed in line with the protocol; and how this system will be applied to regular repeat prescriptions.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4127", "label" : {"_value" : "Biography information for Julie Elliott"} } , "tablingMemberConstituency" : {"_value" : "Sunderland Central"} , "tablingMemberPrinted" : [{"_value" : "Julie Elliott"} ], "uin" : "219428"} , {"_about" : "http://data.parliament.uk/resources/1058775", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1058775/answer", "answerText" : {"_value" : "
For cancers diagnosed up to, and including 2017, the Tumour, Node, Metastasis (TNM7) classification of Malignant Tumours - 7th edition staging system is used. There are 17 cancer sites which have no staging rules in TNM7. These are listed in the following table.<\/p>
<\/p>
ICD Code<\/p><\/td> | Site<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C14<\/p><\/td> | Malignant neoplasm of other and ill-defined sites in the lip, oral cavity and pharynx<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C33<\/p><\/td> | Malignant neoplasm of trachea<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C37<\/p><\/td> | Malignant neoplasm of thymus<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C39<\/p><\/td> | Malignant neoplasm of other and ill-defined sites in the respiratory system and intrathoracic organs<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C46<\/p><\/td> | Kaposi's sarcoma<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C70<\/p><\/td> | Malignant neoplasm of meninges<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C71<\/p><\/td> | Malignant neoplasm of brain<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C75<\/p><\/td> | Malignant neoplasm of other endocrine glands and related structures<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C77<\/p><\/td> | Secondary and unspecified malignant neoplasm of lymph nodes<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C78<\/p><\/td> | Secondary malignant neoplasm of respiratory and digestive organs.<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C79<\/p><\/td> | Secondary malignant neoplasm of other and unspecified sites<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C80<\/p><\/td> | Malignant neoplasm without specification of site<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C88<\/p><\/td> | Malignant immunoproliferative diseases and certain other B-cell lymphomas<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C92<\/p><\/td> | Myeloid Leukaemia<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C93<\/p><\/td> | Monocytic Leukaemia<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C95<\/p><\/td> | Leukaemia of unspecified cell type<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C96<\/p><\/td> | Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue<\/p><\/td><\/tr><\/tbody><\/table> <\/p> This can be viewed on the Union for International Cancer Control (UICC) website at the following link:<\/p> <\/p>
|